p-tau217 blood tests predict Alzheimer’s symptom onset years in advance
Updated
Updated · Fox News · May 5
p-tau217 blood tests predict Alzheimer’s symptom onset years in advance
5 articles · Updated · Fox News · May 5
An NIH-funded Nature Medicine study of more than 600 symptom-free older adults estimated onset within a median three to four years, with higher p-tau217 linked to earlier symptoms.
Researchers said the models could aid trials, but experts cautioned they need broader validation and are not yet accurate enough for individual clinical use.
The Alzheimer’s Association says blood biomarkers should complement specialist assessment for cognitively impaired patients, warning of variable test quality, false positives and limited evidence for screening people without symptoms.
New blood tests can predict Alzheimer's decades in advance, but can medicine actually stop it?
With tests affected by kidney disease and anemia, how reliable are these new Alzheimer's blood markers?
Could early Alzheimer's screening create a generation of 'pre-patients' burdened by anxiety and discrimination?
Breakthrough Blood Test Lumipulse G and the Alzheimer's Clock: Advancing Early Detection with Plasma p-tau217
Overview
In May 2025, the FDA cleared the Lumipulse G pTau 217/β-Amyloid Ratio Test, the first blood-based diagnostic for detecting Alzheimer's amyloid pathology in adults aged 50 and older with cognitive decline. This less invasive and more affordable test offers a simpler alternative to costly PET scans or lumbar punctures, potentially expanding access through insurance coverage. The test measures p-tau217, a leading biomarker whose rising levels after amyloid accumulation enable prediction of symptom onset. However, limitations include risks of false results and ethical concerns, especially for asymptomatic screening. Emerging dried blood spot technology promises easier, remote sampling, but broad use requires careful ethical safeguards and clinical integration.